Država: Velika Britanija
Jezik: engleski
Izvor: MHRA (Medicines & Healthcare Products Regulatory Agency)
Clonazepam
Rosemont Pharmaceuticals Ltd
N03AE01
Clonazepam
400microgram/1ml
Oral solution
Oral
Schedule 4 (CD Benz)
Valid as a prescribable product
BNF: 04080100; GTIN: 5016119150890
0 10 20 30 40 50 60 70 80 90 100 JOB INFORMATION Product Name: Strength: Keyline Ref: Font Type: Font Size: Pharmacode: Dimensions: EAN Code: Folded Size: No. of Colours: Tabbed: Pack Size: Bottle Size: Design Icon: Print Colours: Non-print Colours: New Item Code: Previous Item Code: Supplier Code: Page Number: COLOURS ARTWORK VERSION: Date: Date: Operator: Operator: PREFLIGHT VERSION: JOB SPECIFICATION MAIN BODY TEXT Univers LTD Std 55 Roman UNIVERS LTD STD 65 BOLD 2mg/5ml BLACK CUTTER UKL445 337 300 x 330mm N/A 150 x 37mm 1 9pt No 150ml 150ml N/A H3MD1RBJ1 P0760 N/A 1 of 2 Clonazepam Rosemont 2mg/5ml Oral Solution 15/06/17 - DH - 4 - APPROVALS THIRD PARTY APPROVAL REQUIRED Name: Name: Signature: Signature: Date: Date: AUTHORITY APPROVAL SUPPLIED REGULATORY SIGN-OFF YES YES NO N/A TICK APPLICABLE BOX TICK APPLICABLE BOX SEXUAL n loss of sex drive n difficulty getting or keeping an erection (erectile dysfunction). WITHDRAWAL SYMPTOMS Using benzodiazepines like Clonazepam may make you dependent on the medicine. This means that if you stop treatment quickly, or reduce the dose too quickly, you may get withdrawal symptoms. The most common symptoms can include: n problems sleeping n muscle pain, shaking (tremor) or feeling restless n feeling very anxious, tense, confused, irritable or agitated, or changes in your mood n increased sweating n headache. Less common withdrawal symptoms can include: n feeling sensitive to light, noise or physical contact n seeing or hearing things that are not really there (hallucinations) n tingling and feeling numb in your arms and legs n a feeling of losing contact with reality. INJURY n Patients taking benzodiazepine medicines are at risk of falling and breaking bones. This risk is increased in the elderly and those taking other sedatives (including alcohol). If any of the side effects gets serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist. REPORTING OF SIDE EFFECTS If you get any side effects, talk to your doctor or pharma Pročitajte cijeli dokument
OBJECT 1 CLONAZEPAM ROSEMONT 2MG/5ML ORAL SOLUTION Summary of Product Characteristics Updated 21-Sep-2017 | Rosemont Pharmaceuticals Limited 1. Name of the medicinal product Clonazepam Rosemont 2mg/5ml Oral Solution 2. Qualitative and quantitative composition Each 5ml contains 2mg Clonazepam Excipients with known effects: Ethanol – 100mg/5ml For the full list of excipients, see section 6.1. 3. Pharmaceutical form Oral solution A clear, pale straw coloured oily solution 4. Clinical particulars 4.1 Therapeutic indications Clonazepam Rosemont Oral Solution is indicated in all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements. 4.2 Posology and method of administration Posology The 0.5mg/5ml oral solution may facilitate the administration of lower daily doses in the initial stages of treatment or treatment for the elderly. The 2mg/5ml oral solution should be used for maintenance and maximum dosage regimens. _Adults_ Initial dosage should not exceed 1mg/day. The maintenance dosage for adults normally falls within the range 4 to 8mg. _Elderly_ The elderly are particularly sensitive to the effects of centrally depressant drugs and may experience confusion. It is recommended that the initial dosage of clonazepam should not exceed 0.5mg/day. These are total daily dosages which should be divided into 4 doses taken at intervals throughout the day. If necessary, larger doses may be given at the discretion of the physician, up to a maximum of 20mg daily. The maintenance dose should be attained after 2 to 4 weeks of treatment. _Paediatric Population_ Due to the presence of ethanol in the formulation, this product is not indicated for paediatric use. METHOD OF ADMINISTRATION A 2.5ml/ 5ml double ended spoon with a furth Pročitajte cijeli dokument